WEE1 and ovarian cancer: In a recently presented phase II clinical trial (NCT03579316), the WEE1 inhibitor adavosertib showed promising clinical activity both as monotherapy and in combination with Olaparib, in patients with recurrent ovarian cancer irrespective of BRCA mutational status.